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Cancer cell lines have frequently been used to link drug sensitivity and resistance with
genomic profiles. To capture genomic complexity in cancer, the Cancer Genome Project
(CGP) (Garnett et al., 2012) screened 639 human tumor cell lines with 130 drugs
ranging from known chemotherapeutic agents to experimental compounds. Questions
of interest include: i) can cancer-specific therapeutic biomarkers be detected, ii) can
drug resistance patterns be identified along with predictive strategies to circumvent
resistance using alternate drugs, iii) can biomarkers of drug synergies be predicted ? To
tackle these questions, following statistical challenges still exist: i)biomarkers cluster
among the cell lines; ii) clusters can overlap (e.g. a cell line may belong to multiple
clusters); iii) drugs should be modeled jointly. We introduce a multivariate regression
model with a latent overlapping cluster indicator variable to address above issues. A
generalized finite mixture of multivariate regression (FMMR) model in connection with
the new model and a new EM algorithm for fitting are proposed. Re-analysis of the
dataset sheds new light on the therapeutic inter-relationships between cancers as well
existing and novel drug behaviors for the treatment and management of cancer.
Key Words: Cancer biomarkers; EM algorithm; finite mixture of multivariate regression
model; LASSO; overlapping clustering.
1 Introduction
1.1 Data Description
The use of drugs to selectively target specific genetic alterations in defined patient subpopu-
lations has seen significant successes. One example can be found in the treatment of chronic
myeloid leukaemia (CML) where the first consistent chromosomal abnormality associated
with a human cancer was identified back in the 1960s. Fast forward to the 1980s where the
consequence of this abnormality was discovered to be the production of an abnormal gene
called BCR-ABL. Intense drug discovery programs were initiated to shut down the activity
of BCR-ABL, and in 1992, imatinib (Gleevec) was developed. In 1998, the drug was tested
in CML patients who had exhausted standard treatment options and whose life expectancy
was limited, with remarkable results in their blood counts returning to normal. In 2001, the
FDA approved imatinib. Today, a once commonly fatal cancer now has a five-year survival
rate of 95% (Druker et al., 2006).
Achievements like this largely inspire today’s high throughput screening studies of link-
ing cancer drugs (known or in development) to specific genomic changes which could be
used as therapeutic biomarkers. The hope is that such analyses will shed light on biological
mechanisms underlying drug sensitivity, tumor resistance and potential drug combination
synergies.
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2 Liu and Rao
Cancer cell lines have frequently been used as a convenient way of conducting such
studies. For a systematic search of therapeutic biomarkers to a variety of cancer drugs, the
Cancer Genome Project (CGP) (Garnett et al., 2012) screened 639 human tumor cell lines,
which represent much of the tissue-type and genetic diversity of human cancers, with 130
drugs. These drugs, including approved drugs, drugs in development as well as experimental
tool compounds, cover a wide range of targets and processes involved in cancer biology. A
range of 275–507 cell lines were screened for each drug. The effect of a 72h drug treatment on
cell viability was examined to derive such measures of drug sensitivity as the half-maximal
inhibitory concentration (IC50). The cell lines underwent sequencing of 64 known cancer
genes, genome-wide analysis of copy number gains and losses, and expression profiling of
14,500 genes.
Given the degree of complexity of this dataset, the multivariate analysis of variance
(MANOVA) and the Elastic-Net regression applied in Garnett et al. (2012) are insufficient
for precise knowledge discovery. First, the marginal drug-feature associations discovered
in MANOVA rarely reflect true relationships, as it is more likely that sensitivity of cancer
cells to drugs depends on a multiplicity of genomic and epigenomic features with potential
interactions. Second, the Elastic-Net regression fails to concern following issues: 1) since
the 639 cell lines come from a variety of cancer tissue types, there is likely additional
heterogeneity manifested as subpopulations with overlaps in data; 2) note that the 130
drugs (response variables) are hardly independent, one can improve the prediction accuracy
by modeling with multiple drugs (Breiman and Friedman, 1997).
Moreover, there are some direct questions of interest from a subject matter perspective
that we want to address. These include, i) can cancer-specific therapeutic biomarkers be
detected, ii) can drug resistance patterns be identified along with predictive strategies to
circumvent resistance using alternate drugs, iii) can biomarkers of combination therapies
be identified to help predict synergies in drug activities ? To tackle these questions and
previously discussed statistical challenges, we propose a multivariate regression model with
a latent overlapping cluster indicator variable. Fitting procedures inducing concurrent
variable selection are introduced.
The rest of the paper is organized as follows. In Section 1.2, we give a selective overview
of existing clustering and overlapping clustering methods for general (without response vari-
ables) and regression data. In Section 2, a new statistical model is introduced, a generalized
FMMR model in connection with the new model and a new EM algorithm for fitting are
provided. We also establish a type of consistency optimality for estimation of the general-
ized FMMR model and perform some small simulation studies to empirically demonstrate
this. In Section 3, we put forward another fitting solution to the new model for comparison
with the generalized FMMR model. Section 4 contains a comprehensive re-analyses of the
CGP data using the proposed method. Discussion is included in Section 5.
1.2 Relevant Statistical Literature Review
Clustering is a well established technique to group data elements based on a measure of
similarity. Traditional clustering techniques generate partitions so that each data point
belongs to one and only one cluster. It has long been recognized that such ideal partition
seldom exists in real data (Needham, 1965). It is more likely that clusters overlap in some
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parts. To handle the overlapping issue, Lazzeroni and Owen (2002) put forward the well-
known plaid model for two-sided overlapping clustering for gene expression data, see also
Turner et al. (2005) for improved plaid model and Zhang (2010) for Bayesian plaid model
formulation. Its numerical solution, however, produces unsatisfactory cluster retrievals
(see Section 3). Other overlapping clustering methods include the “naive” finite mixture
(FM) model with a hard threshold on posterior membership probabilities, the probabilistic
model (Banerjee et al., 2005) and the multiplicative mixture model based approach (Fu and
Banerjee, 2008).
More often interest centers on investigating the relationship between response variables
Y ∈ Rq and covariates X ∈ Rp by fitting a regression model rather than to explore the X or
Y on its own. In regression analyses with q = 1, finite mixture of regression (FMR) models
are commonly used to capture unobserved cross-sectional heterogeneity in the data (Jedidi
et al., 1996). The FMR model postulates that a sample of observations come from a finite
mixture of latent partitioning sub-populations with each sub-population represented by a
regression model. It was first introduced to statistical literatures by Quandt (1972). De-
Sarbo and Cron (1988) proposed an EM algorithm (Dempster et al., 1977) based maximum
likelihood estimation for the FMR model. Khalili and Chen (2012) put forward a penalized
likelihood approach for variable selection in FMR models. As a natural generalization to
multivariate responses case, Jones and McLachlan (1992) introduced the FMMR model.
Grun and Leisch (2008) proposed a R package flexmix for fitting FMMR models, however
it assumes that the response variables are independent.
2 The Proposed Method
2.1 Statistical modeling
For a sample (of cell lines) of n observations, denote yi = (yi1, . . . , yiq)
T ∈ Rq a vector
of responses (IC50 values), xi = (xi1, . . . , xipn)
T ∈ Rpn a vector of predictors (genomic
markers) and εi = (εi1, . . . , εiq)
T a vector of random errors for the ith observation. Assume
εi
iid∼ Nq(0,Σ) for i = 1, . . . , n. The following proposed model allows overlapping clustering
for multivariate regression data,
yi =
K∑
k=1
BTk xiPik + εi, i = 1, . . . , n, (1)
where K is the total number of clusters, Bk is an unknown pn × q coefficient matrix for
the kth cluster, and Pik ∈ {0, 1} is 1 if observation i belongs to the kth cluster, otherwise
0. In traditional clustering problem, it assumes that each observation belongs to exactly
one cluster, namely
∑K
k=1 Pik = 1 for all i. Therefore we allow
∑K
k=1 Pik ≥ 1 so that each
observation can belong to multiple clusters.
We provide some interpretation for the clusters in model (1). A cluster k contains a
subset of observations for whom Pik = 1. We postulate that not all genomic features are
relevant in describing the cluster k, thus assume a sparse coefficient matrix Bk. Since the
sparse patterns can vary with k, each cluster is represented by a unique set of biomarkers.
For observations belong to multiple clusters, their response variables are explained by multi-
ple sets of biomarkers, indicative of involving in several biological processes simultaneously.
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2.2 The FMMR model
When
∑K
k=1 Pik = 1, model (1) can be characterized by a hierarchical structure which ends
up with an FMMR model. Consider a latent cluster membership random variable zi for
observation i from (1). Given
∑K
k=1 Pik = 1, the range of zi equals to {1, . . . ,K}. Assume
that P (zi = k) = pik for each k, then
∑K
k=1 pik = 1 and pik ≥ 0. Response yi from model (1)
satisfies
(yi | zi = k,xi,Bk,Σ) ∼ Nq(BTk xi,Σ). (2)
Denote Θ = (B1, . . . ,BK ,Σ, pi) with pi = (pi1, . . . , piK−1)T . We can derive the joint
density of yi and zi as
f(yi, zi | xi,Θ) =
K∏
k=1
{pikf(yi | zi = k,xi,Bk,Σ)}I(zi=k) . (3)
Summarizing (3) over zi = 1, . . . ,K yields the FMMR model
f(yi | xi,Θ) =
K∑
k=1
pikf(yi | zi = k,xi,Bk,Σ). (4)
When using the EM algorithm to estimate model (4), (xi,yi) is regarded as incomplete
data for missing zi, so one works on the complete joint density in (3). For a sample of n
observations from (1), the complete log-likelihood function of Θ becomes
ln(Θ) =
n∑
i=1
K∑
k=1
zik log pik +
n∑
i=1
K∑
k=1
zik log f(yi | zi = k,xi,Bk,Σ), (5)
where zik = I(zi = k).
Since we do not expect all genomic markers to be informative, variable selection, to
obtain a parsimonious model is necessary. Khalili and Chen (2012) and Khalili and Lin
(2013) (for diverging model size) introduced a penalized likelihood approach for variable
selection in FMR models, which was shown consistent in variable selection and highly
efficient in computation. We define a penalized complete log-likelihood function as
l˜n(Θ) = ln(Θ)− ρn(Θ), (6)
where
ρn(Θ) =
K∑
k=1
pikρnk(Bk).
The following two penalty functions are currently used to meet different demands in
variable selection:
1) the L1-penalty in LASSO (Tibshirani, 1996) for simultaneous estimation and variable
selection
ρnk(Bk) = λk‖Bk‖1
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Figure 1: Overall overlapping patterns given K = 3.
2) a linear combination of the L1- and L2-penalty in Elastic-Net (Zou and Hastie, 2005)
for simultaneous estimation and selection of grouped features
ρnk(Bk) = λk1‖Bk‖1 + λk2‖Bk‖22,
where ‖ · ‖1 and ‖ · ‖2 are respectively the L1- and L2-norms and the tuning parameters
λk, λk1, λk2 ≥ 0. The L1-penalty is singular at the origin, thus can shrink some coefficients
to exact 0 for sufficiently large λk or λk1 (Fan and Li, 2001).
Their revised EM algorithm can easily be generalized to maximize l˜n(Θ) in (6), hence
we bypass here. In next section, generalized FMMR model and EM algorithm are devised
to fit overlapping multivariate regression data.
2.3 The Generalized FMMR Model
Finite mixture models (including FMR and FMMR) can only fit partitions, as can be seen
from Section 2.2. To enable overlapping clustering, one often uses a ”naive” approach by
applying a hard threshold α to finite mixture models. This approach assigns a sample to
cluster k if its posterior probability of belonging to cluster k is larger than a pre-specified
α, hence enabling a sample to belong to multiple clusters. As pointed out by Banerjee
et al. (2005), this method is problematic because it is not a natural generative model
for overlapping clustering, since one underlying assumption of the finite mixture model is
that each observation comes from one and only one mixture component. In this section
however, we introduce a generalized FMMR model to retrieve overlapping clusters when∑K
k=1 Pik ≥ 1. This generalized model retains its ability in fitting partitions.
Suppose we have K objective clusters indexed by 1 to K. These objective clusters refer
to clusters defined in (1) and can overlap with each other, resulting in 2K − 1 types of
overlapping patterns. Let K equal to 3 for an example, overall overlapping patterns are
then composed of S = {1, 2, 3, 12, 13, 23, 123}. Figure 1 shows the particular part each
overlapping pattern in S represents. By definition, overlapping patterns in S are mutually
exclusive. And each observation i from (1) belongs to one and only one overlapping pattern.
In the next, we define 2K − 1 hypothetical clusters. Each hypothetical cluster (simply
called “cluster” since after) represents an overlapping pattern defined in advance and is
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indexed by an element in T ,
T = ∪Ks=1 {(l1 . . . ls) : {l1, . . . , ls} ⊆ {1, . . . ,K}} .
Cluster (l1 . . . ls) implies its members belonging to objective clusters l1, . . . , ls.
We now introduce a latent cluster membership random variable zi for observation i from
model (1) and characterize the model via a hierarchical structure. Given
∑K
k=1 Pik ≥ 1, the
range of zi becomes T . Further define
P (zi = (l1 . . . ls)) = pi(l1...ls). (7)
Then vector pi = (pi(l1...ls)∈T )
T has∑
(l1...ls)∈T
pi(l1...ls) = 1, pi(l1...ls) ≥ 0.
Response yi from (1) satisfies
(yi | zi = (l1 . . . ls),xi, {Blk}sk=1,Σ) ∼ Nq
(
s∑
k=1
BTlkxi,Σ
)
. (8)
Let Θ = (B1, . . . ,BK ,Σ, pi). By (7) and (8), the joint density of yi and zi equals
f(yi, zi | xi,Θ) = (9)∏
(l1...ls)∈T
{
pi(l1...ls)f (yi | zi,xi, {Blk}sk=1,Σ)
}I(zi=(l1...ls)) .
Summarizing (9) over zi leads to the generalized FMMR model
f(yi | xi,Θ) =
∑
(l1...ls)∈T
pi(l1...ls)f (yi | zi,xi, {Blk}sk=1,Σ) . (10)
Note that if pi(l1...ls) = 0 for s > 1, (10) reduces to the traditional FMMR model in (4).
Then the (conditional) log-likelihood function of Θ for a sample of n observations from
(1) is
l0n(Θ) =
n∑
i=1
log
 ∑
(l1...ls)∈T
pi(l1...ls)f (yi | zi,xi, {Blk}sk=1,Σ)
 .
Maximizing above ordinary likelihood function yields non-zero estimates for all regres-
sion coefficients. To induce variable selection and remove noise predictors from the regres-
sion model, we propose a penalized log-likelihood function
l˜0n(Θ) = l
0
n(Θ)−
K∑
k=1
∑
(l1...ls):
k∈{l1,...,ls}
pi(l1...ls)ρnk(Bk), (11)
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where ρnk(Bk) is the LASSO or Elastic-Net penalty function in Section 2.2. Notation∑
(l1...ls):
k∈{l1,...,ls}
indicates that it summarizes over (l1 . . . ls) ∈ T for which k ∈ {l1, . . . , ls}.
The penalty imposed on Bk is proportional to
∑
(l1...ls):
k∈{l1,...,ls}
pi(l1...ls), which by definition is
proportional to the number of observations involved in the kth objective cluster. This is
a strategy, similar to Khalili and Chen (2012), of relating the penalty to sample sizes for
enhanced power of the method.
2.4 Numerical Solution to the Generalized FMMR Model
We use the renowned EM algorithm for optimization of the generalized FMMR model. The
complete log-likelihood function of Θ is
ln(Θ) =
n∑
i=1
∑
(l1...ls)∈T
zi,(l1...ls) log pi(l1...ls)
+
n∑
i=1
∑
(l1...ls)∈T
zi,(l1...ls) log f (yi | zi,xi, {Blk}sk=1,Σ) ,
where zi,(l1...ls) = I(zi = (l1 . . . ls)).
The penalized complete log-likelihood function for concurrent variable selection is then
l˜n(Θ) = ln(Θ)−
K∑
k=1
∑
(l1...ls):
k∈{l1,...,ls}
pi(l1...ls)ρnk(Bk). (12)
Due to the overlap setting, each Bk involves in multiple clusters. Therefore coefficient
matrix Bk for k = 1, . . . ,K can not be optimized independently like in usual EM algorithm.
Instead we sequentially update Bk given the rest are known. Specifically take ρnk(Bk) as a
LASSO penalty function for an example, our revised EM algorithm iteratively maximizes
l˜n(Θ) in two steps:
E-step: Given Θm, estimate zmi,(l1...ls) with its posterior probability by applying the
Bayes’ rule to (9) and (10),
Pˆ (zmi,(l1...ls) = 1 | yi,xi,Θm) =
pim(l1...ls)f (yi | zi,xi, {Blk}sk=1,Σm)∑
(l′1...l′s)∈T pi
m
(l′1...l′s)
f
(
yi | zi,xi, {Bl′k}sk=1,Σm
) .
M-step: Given Zm = (zmi,(l1...ls)), update the mixing proportions pi
m+1 by
pim+1(l1...ls) =
1
n
n∑
i=1
zmi,(l1...ls), (l1 . . . ls) ∈ T.
Note that this is obtained by maximizing the leading term of (12) with respect to pi. This
simplified updating scheme however works well in simulation studies.
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Given Zm, pim+1 and Σm, sequentially update Bm+1k | {Bms }s=Ks=1,s 6=k by
Bm+1k = arg maxBk
n∑
i=1
∑
(l1...ls):
k∈{l1,...,ls}
zmi,(l1...ls) log f
(
yi | zi,xi, {Bmlj }sj=1,lj 6=k,Σm
)
−
∑
(l1...ls):
k∈{l1,...,ls}
pim+1(l1...ls)λk‖Bk‖1. (13)
By (8),
Bm+1k = arg minBk
∑
(l1...ls):
k∈{l1,...,ls}
tr
(
(Y∗ −XBk)T zm(l1...ls)(Y∗ −XBk)(Σm)−1
)
+2
∑
(l1...ls):
k∈{l1,...,ls}
pim+1(l1...ls)λk‖Bk‖1, (14)
where
y∗i = yi −
∑
l∈{l1,...,ls}\k
(Bml )
Txi, Y
∗ = (y∗1, . . . ,y
∗
q),
zm(l1...ls) = diag
(
zm1,(l1...ls), . . . , z
m
n,(l1...ls)
)
.
Above (14) is a multivariate regression problem with a LASSO penalty for estimation, which
can be solved by the MRCE algorithm (Rothman et al., 2010). If we ignore the covariance
structure of Σm merely in (14), estimation of Bm+1k reduces to q independent LASSO
regression problems. In this case, more complex penalty functions such as the Elastic-Net
and fused LASSO penalties can easily be applied. Therefore we also have investigated
the performance of this simplified strategy in simulation studies. It works surprisingly
comparable to original method utilizing the MRCE algorithm for estimation of Bm+1k .
Given Zm and {Bm+1k }Kk=1, update Σm+1 by
Σm+1 = arg max
Σ
n∑
i=1
∑
(l1...ls)∈T
zmi,(l1...ls) log f
(
yi | zi,xi, {Bm+1lk }sk=1,Σ
)
= arg min
Σ
n∑
i=1
∑
(l1...ls)∈T
−zmi,(l1...ls) log |Σ−1|
+
∑
(l1...ls)∈T
tr
(
(Y −X
s∑
k=1
Bm+1lk )
T zm(l1...ls)(Y −X
s∑
k=1
Bm+1lk )Σ
−1). (15)
By taking the derivative of (15) according to Σ−1, we get
Σm+1 =
∑
(l1...ls)∈T (Y −X
∑s
k=1 B
m+1
lk
)T zm(l1...ls)(Y −X
∑s
k=1 B
m+1
lk
)∑
(l1...ls)∈T
∑n
i=1 z
m
i,(l1...ls)
,
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where
∑
(l1...ls)∈T
∑n
i=1 z
m
i,(l1...ls)
= n.
Although we can also penalize the inverse covariance matrix Σ−1 of (15) like in Rothman
et al. (2010), simulations (not presented in the paper) show that penalizing Σ−1 results in
a lower degree of clustering accuracy than not penalizing Σ−1. This may be because by
penalizing Σ−1 one introduces bias into its estimation, a biased estimate of Σ−1 in return
deteriorates the estimate of zi,(l1...ls) in E-step. Thus we choose to not penalize Σ
−1.
Commencing with an initial value Θ0, the algorithm iterates between E- and M-steps
until the relative change in log-likelihood, |(lm+1n (Θˆ) − lmn (Θˆ))/lmn (Θˆ)|, is smaller than
some threshold value, taken as 10−5 in simulation studies and 10−3 in real data analysis.
Additionally, a cluster, whose mixing proportion is smaller than some threshold value taken
as 0.01 in the paper, will be removed during iterations to avoid over estimations.
2.5 Selection of Tuning Parameters and the K
In preceding penalized likelihood approach, one needs to choose the values of component-
wise tuning parameters λk for k = 1, . . . ,K, which controls the complexity of an estimated
model. The data-driven method cross-validation (CV) (Stone, 1977) is frequently adopted
in literatures. Here we use a component-wise 10-fold CV method for tuning parameters
selection in (14).
Moreover, selection of the number of components K is essential in finite mixture models
(including FMR and FMMR). In applications, the choice can be based on prior knowledge of
data analysts. With respect to formatted methodologies, information criteria (IC) remains
by far the most popular strategy for selection of K. See Claeskens et al. (2008) for general
treatments on this topic. Here we choose the K minimizing below ICn,
ICn(K) = −2ln(Θ) +NKan. (16)
Above Nk is the effective number of parameters in the model,
NK = |{Bk, k = 1, . . . ,K}|+ |pi| − 1 + |Σ|,
where |A| calculates the number of nonzero elements in A. In (16), an is a positive sequence
depending on n. The well known AIC (Akaike, 1974) and BIC (Schwarz et al., 1978)
correspond to an = 2 and an = log(n) respectively. It was shown in Keribin (2000) that
under general regularity conditions, BIC can identify the true order of a finite mixture
model asymptotically. Feasibility of his results to FMR or FMMR models is unknown yet.
We examined the performance of BIC for selection of K in a generalized FMMR model via
simulation studies. It obtained a high degree of accuracy.
2.6 The Asymptotic Properties and Simulation Studies
Khalili and Lin (2013) showed that their approach by maximizing a penalized log-likelihood
function for estimation of the FMR model is consistent in both estimation and variable
selection under certain regularity conditions. Denote f(w; Θ) the joint density function of
data w = (x,y) with Θ ∈ Ω. The conditional density function of y given x follows an FMR
model in Khalili and Lin (2013) and a generalized FMMR model in (10) in our paper. As
defined in (11), the penalized log-likelihhood function is a summation of the log(f(wi; Θ))’s
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minus a penalty function. Because the regularity conditions for asymptotic establishments
in Khalili and Lin (2013) are made on f(w; Θ) and the penalty function directly, their
theoretical achievements can be extended to our problem.
Denote Bjk the jth column of Bk for j = 1, . . . , q. Let B
j
k = (B
j
k1,B
j
k2) to divide the
coefficient vector into non-zero and zero subsets. Denote Θ0 the true value of Θ, Θ0 =
(Θ01,Θ
0
2) is the corresponding decomposition such that Θ
0
2 contains all zero coefficients, and
Θˆn = (Θˆn1, Θˆn2) is its estimate. Since the dimension of Θˆn1 increases with n, we investigate
the asymptotic distribution of its finite linear transformation, DnΘˆn1, where Dn is an l×dn1
constant matrix with a finite l and dn1 is the dimension of Θ
0
1. Moreover DnD
T
n → D and
D is a positive definite and symmetric matrix. We assume that K is independent of the
sample size n and known beforehand. Its selection is discussed in Section 2.5.
Lemma 1. Suppose the penalty function ρnk(Bk) satisfies conditions P0−P2 and the joint
density function f(w; Θ) satisfies conditions R1 −R5 in Khalili and Lin (2013).
1. If p
4
n
n → 0, then there exists a local maximizer Θˆn for the penalized log-likelihood
l˜n(Θ) with
‖Θˆn −Θ0‖ = Op
{√
pn
n
(1 + q2n)
}
,
where q2n = maxkij
{
|ρ′nk(b0kij)|√
n
: b0kij 6= 0
}
, b0kij is an entry of B
0
k.
2. If ρnk(Bk) also satisfies condition P3 in Khalili and Lin (2013) and p
5
n
n → 0, for any√
n/pn-consistent maximum likelihood estimate Θˆn, as n→∞ it has:
i. Variable selection consistency:
P (Bˆjk2 = 0)→ 1, k = 1, . . . ,K and j = 1, . . . , q.
ii. Asymptotic normality:
√
nDnI−1/21 (Θ01)
{[
I1(Θ01)−
ρ′′n(Θ01)
n
]
(Θˆn1 −Θ01) +
ρ′n(Θ01)
n
}
→d N(0,D), (17)
where I1(Θ01) is the Fisher information matrix under the true subset model.
Proof. Write Θ = (θ1, θ2, . . . , θtn)
T , where tn is the total number of parameters in the
model. Then Lemma 1 is a direct extension from Khalili and Lin (2013).
By Lemma 1, Θˆn under the LASSO or Elastic Net penalty has a convergence rate
√
pn/n
via appropriate choice of the tuning parameters. However consistent estimation does not
necessarily guarantee consistent variable selection. By the Lemma, the LASSO or Elastic
Net penalty does not lead to consistent variable selection, because on one hand λk must
be large enough to achieve sparsity, on the other hand the bias term q2n is proportional to
the λk/
√
n. This problem can be solved by using adaptive LASSO or adaptive Elastic Net
penalty instead, which leads to concurrent estimation and variable selection consistency.
We conducted a sequence of small simulation studies to numerically demonstrate opti-
mality properties of the new method. They are presented in Web Appendix A.
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3 Generalization of the Plaid Model
Lazzeroni and Owen (2002) proposed the plaid model to decompose a gene expression data
as the sum of overlapping layers (clusters). Each layer contains a subset of genes and
samples, while each gene and sample can participate in multiple layers. Denote xij a gene
expression data entry and K is the total number of layers. The plaid model is
xij = ω0 +
K∑
k=1
(ωk + αik + βjk)PikQjk,
where ω0, ωk, αik, βjk ∈ R, Pik is 1 if gene i is in the kth gene-bolck and otherwise 0, Qjk
is 1 if sample j is in the kth sample-block and otherwise 0. An iterative algorithm was put
forward to consecutively search for the layers.
In fact, model (1) is a generalized plaid model by introducing covariates into the model
so that it can cluster overlapping multivariate regression data. Therefore, estimation pro-
cedures of the plaid model can also be used to estimate (1). In parallel to the plaid model,
the parameters are estimated by minimizing the Q,
Q =
1
2
n∑
i=1
‖yi −
K∑
k=1
xTi BkPik‖22 +
K∑
k=1
ρnk(Bk),
where ρnk(Bk) is the penalty function defined in Section 2.2.
Detailed procedures for optimizing Q are shown in Algorithm 1 in Web Appendix B,
which is a generalization of the improved iterative algorithm by Turner et al. (2005) to
multivariate regression. At each time, the algorithm searches for a layer that explains as
much of the rest data as possible; once a layer has been found, it is subtracted from the data
and remains unchanged; the algorithm stops when no further layers can be found. However
this algorithm introduces bias to parameter estimations due to its discrete updating scheme,
where previous recruited layers can not be refined as new layers are recruited into the model.
To address this issue, we further revised Algorithm 1 to enable joint optimization of all
layers. Detailed procedures are presented in Algorithm 2 in Web Appendix B.
4 Therapeutic Biomarker Identification for the CGP Data
We now turn our attention back to analyses of the CGP high throughput drug sensitivity
dataset for cancer described in Section 1.1. An updated version of this data
(http://www.cancerrxgene.org/downloads/) contains 707 human tumor cell lines as sam-
ples, 140 drugs as response variables, and 13831 genomic features as covariates (including
the tissue type, rearrangements, mutation status of 71 cancer genes, continuous copy num-
ber data of 426 genes causally implicated in cancer, as well as genome-wide transcriptional
profiles). The response variables, made up with IC50 values from pairwise drug-cell-line
screening, have some missing values. Therefore the data was first filtered by removing cell
lines for which less than 50% of the drugs were tested, resulting in 591 cell lines remaining.
In the remaining data, about 37.4% of the cell lines are with missing values. These missing
values were then imputed via the a random forest imputation algorithm (Ishwaran et al.,
12 Liu and Rao
2008).
Direct Q1: Can cancer-specific therapeutic biomarkers be detected?
We applied our new method to identify patterns of cancer-specific therapeutic biomark-
ers. Note that by “cancer-specific” we do not assume separate patterns for each cancer
type but rather clusters that may be driven by one or a small number of cancer types.
Throughout the analysis, we fixed K to a value of 3, although as previously shown, a BIC
model selection approach could also be used. However, fixing the value of K does not limit
the interesting findings that we can still find and saves on computational time.
Due to the scale and complexity of the data, the analysis was conducted in three steps.
Although simulation studies show that modeling with multiple response variables yields
much higher clustering accuracy than modeling with a single response variable, it is unrea-
sonable to simply fit all 140 drugs (responses) in one generalized FMMR model. Because
by doing so, one assumes that the cell line assignments to clusters are the same for all 140
drugs, which can hardly be true. Thus in our analysis, we first divided the 140 drugs into
several groups and then fitted each drug group with a generalized FMMR model, in which
to capture active grouped genomic features, the Elastic-Net penalty along with a simplified
updating scheme of Bk discussed in Section 2.4 was used.
In the first step, each drug c was fitted by a generalized FMMR model, from which
we got drug-specific cell line assignments, Zˆc, and cluster-wise coefficient estimates, Bˆ
c
k
for k = 1, . . . , 3. In the second step, we used the affinity-propagation clustering (APC)
algorithm (Frey and Dueck, 2007) to group the 140 drugs based on results from step 1. The
grouping was conducted in a two-level nested manner. In the first level, the APC algorithm
was applied to all 140 drugs. The pair-wise similarity matrix required by the algorithm
as input data was calculated from the Euclidean distance between Zˆa and Zˆb where a and
b refer to two unique drugs. In the second level, the APC algorithm was re-applied to
each first-level drug group. Coefficient estimates Bˆck for k = 1, . . . , 3 were used to calculate
the pair-wise similarities. Consequently, drugs having similar cell line assignments and
cluster-wise coefficient estimates were grouped together. Resulting drug groups are shown
in Web Figure 6, where the coloring and thickness of connecting lines indicate degree of
closeness. In the third step, each second-level drug group C from step 2 was fitted by a
generalized FMMR model, from which we got drug-group-specific cell line assignments, ZˆC ,
and cluster-wise coefficient estimates BˆCk for k = 1, . . . , 3.
As an illustration, cell line members and coefficient estimates of clusters 1 and 12 for
each second-level drug group are shown in Web Figures 7–8. Cell line members of a cluster
are depicted via frequencies of the cancer types cell lines belong to. The frequencies are
represented by the size of colored bubbles in top panel of the figures. Estimates of other
clusters are not presented in the paper due to limited space. It’s very clear that clusters
being driven by different cancer types have very different therapeutic genomic profiles and
yet no clusters are homogeneous in a particular cancer type. This speaks to the great het-
erogeneity seen in cancer overall where in fact, cancer is not thought of as a single disease
but rather many diseases characterized by different underlying biological changes.
Direct Q2: Can drug resistance patterns be identified along with predictive
Precision Therapeutic Biomarker Identification 13
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Figure 2: Subset estimation results of cluster 1 by fitting the data of each second-level
drug group in a generalized FMMR model. Bottom panel shows a subset of the coefficient
estimates corresponding to the mutations of 71 cancer genes, and upper panel shows cell
line compositions of cluster 1 by cancer types.
strategies to circumvent resistance using alternative drugs?
We discussed in the Introduction to the paper the success story of Gleevec which was
used for the treatment of CML based on the known specificity of targeting the BCR-ABL
gene. It is now becoming more and more common in the treatment of cancer to first
sequence known cancer genes in tumor genomes and then design therapies accordingly
(Bailey et al., 2014). It is also true that tumors can develop resistance to first line therapies
by accumulating mutations which confer resistance. We now show how our methodology
can be used to identify predictive strategies for circumventing drug resistance based on
mutation data.
Figures 2–3 are similar to Web Figures 7–8, except that they only show a subset of
BˆC1 and Bˆ
C
12 with regard to the mutations of 71 cancer genes, where Bˆ
C
12 = Bˆ
C
1 + Bˆ
C
2 are
coefficient estimates of cluster 12 for drug group C. Bottom panel of figure 2–3 are in fact
regression based drug-genetic association map with red indicating drug-sensitivity biomark-
ers and blue indicating drug-resistance biomarkers, conditioning on a cluster of cell lines
(upper panel) identified by the generalized FMMR model. We propose that above estima-
tion results can be used for drug repurposing (Martins et al., 2015) for resistant tumors.
Take soft tissue cancers as an example of this drug repurposing. We extracted those clusters
which contain a high percentage of soft tissue cancers (large purple bubbles), along with
the subset cluster-wise coefficient estimates. The extracted information is presented in Web
Figure 5. Its upper panel shows the IC50 values of soft tissue cell lines in extracted clus-
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Figure 3: Subset estimation results of cluster 12 by fitting the data of each second-level
drug group in a generalized FMMR model.
ters. The drugs in Web Figure 5 were further filtered by only keeping those that have low
IC50 values without resistance biomarkers and that have high IC50 values with resistance
biomarkers, leading to Figure 4. In this figure, we conclude that the former set of drugs
can be used as alternatives for the later set of drugs which progress resistance to soft tissue
cancers. As a positive control of this strategy, drug Gemcitabine was found to be effective
in soft tissue cancers resistant to standard chemotherapy (doxyrubicin) in Merimsky et al.
(2000).
Direct Q3: Can drug synergies be predicted?
Our desire to allow overlapping cell line clusters becomes apparent in answering this
question. Overlapping clusters can be used to guide drug combinations and identify poten-
tial drug synergies. From ZˆC , we can get the cluster-wise IC50 values for each drug. Web
Figure 9 are boxplots of the cluster-wise IC50 values for 15 out of 140 drugs. Due to limited
space, the rest are not shown. We then identify the drugs for which the magnitudes of IC50s
of overlapping cluster, say 12, are between those of clusters 1 and 2. For instance, drugs
MS.275 and GW843682X show such interesting pattern. We focus on the cluster with high-
est IC50s on average, say cluster 2, and use the coefficient estimates of overlapping cluster
to guide the search of another drug to decrease the IC50s of cluster 2 towards overlapping
cluster.
Take GW843682X for an example, cluster 2 has the highest IC50s among clusters 1, 2,
and 12. We predicted the IC50s in cluster 2 using Bˆ
gw843682x
1 , Bˆ
gw843682x
2 and Bˆ
gw843682x
12
respectively. Predicted results are shown in top panel (middle) of Figure 5. By doing so,
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Figure 4: The extracted IC50 values of soft tissue cancers (upper panel) and a subset of
the coefficient estimates corresponding to the mutations of 71 cancer genes (bottom panel)
after filtering those drugs not showing the desired pattern.
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Figure 5: Prediction of drug effects and drug combination effects. In each plot, “Tr”
represents the observed IC50 values; the rest three boxplots are predicted IC50 values using
selected coefficient matrices.
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we want to see if coefficients Bˆgw843682x1 or Bˆ
gw843682x
12 applied to cell lines in cluster 2 can
generate low IC50s similar to those in clusters 1 or 12. Since Bˆ
gw843682x
1 corresponds to the
coefficient estimates of the target drug GW843682X, we need to find another drug producing
similar coefficient estimates to Bˆgw843682x1 , this leads to Bˆ
epothilone.b
3 . The predicted IC50s of
cluster 2 using Bˆepothilone.b3 , Bˆ
gw843682x
2 and Bˆ
epothilone.b
3 +Bˆ
gw843682x
2 are presented in bottom
panel (middle) of Figure 5. It shows that the combination of GW843682X and Epothilone.B
produces much lower IC50s for cluster 2 than GW843682X alone. Similar studies were
conducted for MS.275 with respect to its clusters 1, 2, 12 and GW843682X with respect to
its clusters 2, 3, 23. Results are shown in left and right columns of Figure 5 respectively.
The combination of GW843682X and NVP.BEZ235 decreases the IC50s dramatically, while
the combination of MS.275 and Bicalutamide does not show such effect. As a positive
control, Wildey et al. (2014) pointed out that a group of drugs (including GW843682X
and Epothilone B) may provide a practical starting point to investigate combinatorial drug
therapies for synergistic effect in small-cell lung cancer (SCLC). Among the group of drugs,
they found synergism between GW843682X and CGP60474 via a preliminary study.
5 Discussion
In this paper, we proposed a new model for identifying therapeutic biomarkers for cancer
which can answer specific questions regarding sensitivity, resistance and synergy. We used a
penalized likelihood approach for the FMMR model which enforced sparsity in the genomic
features. To enable overlapping clustering, the FMMR model was then generalized and a
new EM algorithm derived for estimation of model parameters. While the noteworthy plaid
model can also be generalized for overlapping clustering multivariate regression data, the
generalized FMMR model markedly outperforms this method.
Some improvements can be made for future developments on this work. First, other
useful penalty functions for multivariate regression estimations can be adopted, such as the
MAP (MAster Predictor) penalty in Peng et al. (2010), the L2SV S method by Simila¨ and
Tikka (2007) and the L∞SV S method by Turlach et al. (2005). Second, the multivariate
normal distribution assumption on Yi can be extended to other more flexible paramet-
ric families of multivariate distributions, such as the skew-normal distribution (Azzalini,
2005) and the multivariate skew-t distribution (Chen et al., 2014), for frequent presence of
skewness and kurtosis in real data.
As described in the CGP data analyses, we had about 37% of the final analyses obser-
vations that had missing data and which we dealt with by using random forest imputation.
It would be of interest to explore the impact of this step more thoroughly. An alternative
would be to generalize to this problem, the recently developed E-MS algorithm Jiang et al.
(2015) for model selection with incomplete data.
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Web-based Supplementary Materials for “Precision
Therapeutic Biomarker Identification with Application to
the Cancer Genome Project”
A Simulation Studies
A.1 Design of the Simulations
Two scenarios were designed to investigate the non-overlapping clustering and overlapping
clustering of the new method respectively. In each scenario, data were generated from model
(2.1) with K = 3, pn = 15, q = 3 and n = 150, 450. Predictors xi, i = 1, . . . , n, were drawn
independently from Npn(0,Σ1) with Σ1(i, j) = 0.5
|i−j|. Random errors εi, i = 1, . . . , n,
were drawn independently from Nq(0,Σ2) with Σ2(i, j) = 0.75
|i−j|.
The sparse coefficient matrices Bk, k = 1, 2, 3, were generated as
Bk = W ⊗ S⊗T, (18)
where ⊗ indicates the element-wise product. Each entry of W was drawn independently
from N(0, 1), each entry of S was drawn independently from the Bernoulli distribution
B(1, p1), and each row of T (either all 1 or all 0) was determined by an independent draw
from B(1, p2). As a result, we expect p1p2pn relevant predictors for each response variable,
and (1 − p2)pn predictors are expected to be irrelevant to all q response variables. We
let p1 = 0.5 and p2 = 0.9. Each simulation was repeated for 50 times. A new sequence of
Bk, k = 1, 2, 3 and a new set of data (X,Y) were generated for each repetition. We assumed
that K is known, so that performance evaluation of the new method is not interfered by
selection of K. Its selection is separately examined in Section A.4.
Scenario 1: The 3 clusters are non-overlapping, each cluster contains n/3 observations.
Scenario 2: 70% of the observations involve in single cluster, 22% of the observations
involve in two clusters and 8% of the observations involve in three clusters.
A.2 Quality Measures of Cluster Recovery
Quality measures in Baeza-Yates et al. (1999) have been used to evaluate the clustering
performance of the proposed method. Denote NS the number of elements in S. Below
quality measures were proposed to compare a retrieved cluster Aˆ with a target cluster A,
“specificity” =
NA∩Aˆ
NA
, “sensitivity” =
NA∩Aˆ
NAˆ
,
“F1 measure” =
2NA∩Aˆ
NA +NAˆ
.
The F1 measure, taken as the harmonic mean of specificity and sensitivity, gives an overall
measure of the clustering.
Moreover, we employed the one-to-one correspondence match approach (Turner et al.,
2005) to evaluate a sequence of retrieved clusters. It includes about three steps. First make
the number of retrieved clusters to be the same as the number of target clusters by adding
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null clusters to retrieved clusters or dropping addition poorly retrieved clusters. Retrieved
clusters are then matched to target clusters in pair. Finally, calculate the mean quality
measures for the sequence of paired clusters.
A.3 Results of the Simulations
A sequence of methods were implemented for comprehensive comparison with our new
method, including the generalized plaid model (plaid) and its revised counterparts (aplaid);
the R package flexmix (EM) where response variables are treated as independent and over-
lap issues are not considered; the generalized FMMR model with response variables treated
as independent (gEMseplasso0); the generalized FMMR model with separate LASSO esti-
mation of Bk (gEMseplasso); and finally the original generalized FMMR model with MRCE
estimation of Bk (gEMmrce).
Their performances were evaluated via the three quality measures introduced in Sec-
tion A.2 and the sum of squared errors (SSE) of coefficients estimates. Results are sum-
marized in Web Figure 6–7. In scenario 1 when there is no overlap, EM and gEMseplasso0
do equally well showing that the generalized FMMR model retains the ability to recover
non-overlapping clusters. By taking into account of the covariance structure among re-
sponse variables, gEMseplasso and gEMmrce outperform EM and gEMseplasso0, but there
is little difference between gEMseplasso and gEMmrce. In scenario 2 when there are 30%
overlaps, specificity of EM drops down dramatically, resulting in a poor F1 measure. The
gEMseplasso0 does much better than EM by estimating the overlaps, while it is defeated
by gEMseplasso and gEMmrce. In this scenario, gEMmrce outperforms gEMseplasso when
n = 150. However, they converge very fast with n, both achieving a median 95% clustering
accuracy when n = 450. The plaid and aplaid have a poor performance in all scenarios.
A.4 Additional Simulations
We conducted another simulation for scenario 2 to evaluate the accuracy of BIC in selection
of K. In the simulation, K is unknown in candidate procedures EM and gEMseplasso, and
is chosen by minimizing the BIC. Results are summarized in Web Figure 8 and Web Table 1.
Given 30% overlaps in simulated data, BIC has a poor performance in identifying the true K
with the EM procedure. Whereas by fitting the overlapping clusters with gEMseplasso, BIC
obtains a much higher accuracy in selection of K (see Web Table 1). Moreover, although K
is misspecified for 12% of the times when n = 450, gEMseplasso still has achieved a median
93% clustering accuracy (see Web Figure 8).
An additional simulation was conducted for scenario 2 to investigate the advantage
of modeling with multivariate response variables in the new method. We compared the
performance of modeling with all 3 response variables versus modeling with each of the
3 response variables in the generalized FMMR model. Results are summarized in Web
Figure 9. Using multivariate response variables leads to a much higher clustering accuracy.
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Algorithm 1 Plaid
For k = 1 : K do
At this point, we have already found k − 1 layers and are searching for the kth layer.
Calculate the residuals from previous k − 1 layers by
zi = yi −
k−1∑
l=1
xTi BlPil, i = 1, . . . , n.
Initialize P0k.
For s = 1 : S do
Given Ps−1k , compute
Bsk = arg min
Bk
1
2
n∑
i=1
‖zi − xTi BkP s−1ik ‖22 +
q∑
j=1
λjk‖bjk‖1,
where Bk = (b1k, . . . ,bqk).
Given Bsk, compute
P sik =
{
0.5 + min{0.5, S2(S−T )}, ‖zi − xTi Bsk‖22 ≤ ‖zi‖22,
0.5−min{0.5, S2(S−T )}, otherwise,
where T was taken as 0.2S for i = 1, . . . , n.
End for
Given PSk , update B
S+1
k .
Given BS+1k , prune layer memberships by
PS+1ik =
{
1, ‖zi − xTi Bk‖22 ≤ τ‖zi‖22,
0, otherwise,
where τ ∈ (0, 1) for i = 1, . . . , n.
Given PS+1k , update B
S+2
k .
Given PS+11 , . . . , P
S+1
k , back fit the layers R times. We set R = 2.
End for
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Algorithm 2 All-plaid
Initialize B01, . . . ,B
0
K and P
0
1, . . . ,P
0
K .
For s = 1 : S do
For k = 1 : K do
Given (Bs1, . . . ,B
s
k−1,B
s−1
k+1, . . . ,B
k−1
K ) and (P
s
1, . . . ,P
s
k−1,P
s−1
k , . . . ,P
s−1
K ), compute
zi = yi −
k−1∑
l=1
xTi B
s
lP
s
il −
K∑
l=k+1
xTi B
s−1
l P
s−1
il , i = 1, . . . , n,
Bsk = arg min
Bk
1
2
n∑
i=1
‖zi − xTi BkP s−1ik ‖22 +
q∑
j=1
λjk‖bjk‖1,
where Bk = (b1k, . . . ,bqk).
Given Bsk, compute
P sik =
{
0.5 + min{0.5, S2(S−T )}, ‖zi − xTi Bk‖22 ≤ τ‖zi‖22,
0.5−min{0.5, S2(S−T )}, otherwise,
where T was taken as 0.2S and τ ∈ (0, 1) for i = 1, . . . , n.
End for
End for
Web Table 1: Accuracy of BIC in selection of K.
sample size EM gEMseplasso
n=150 0.32 0.56
n=450 0.22 0.88
B Two algorithms of the Generalized Plaid Model
Web Tables
Web Figures
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Web Figure 6: Simulation results of scenario 1. The two box plots under each method
correspond to n = 150, 450 respectively.
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Web Figure 10: The extracted IC50 values of soft tissue cancers (upper panel) and a subset of
the coefficient estimates corresponding to the mutations of 71 cancer genes (bottom panel).
Drug names in red indicate type “chemo”, black indicate type “clinical”, blue indicate type
“experimental”, darkblue indicate type “in clinical development” and yellow indicate drug
type not available.
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Web Figure 12: Estimation results of cluster 1 by fitting the data of each second-level drug
group in a generalized FMMR model. Bottom panel plots the coefficient estimates, and
upper panel describes the cell line compositions of cluster 1 by cancer types.
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Web Figure 13: Estimation results of cluster 12 by fitting the data of each second-level drug
group in a generalized FMMR model.
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Web Figure 14: Cluster-wise IC50 values of each drug.
